Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
Iran helicopter crash that killed President Raisi could reverberate across the Middle East
JERUSALEM (AP) — The helicopter crash in which Iranian President Ebrahim Raisi, the country’s foreig2024-05-21Universities axe hundreds of lecturers
Universities are cutting hundreds of teaching posts at the same time as creating 'woke' jobs with sa2024-05-21- LOS ANGELES (AP) — Denis Bouanga scored in the second minute of stoppage time, Timothy Tillman added2024-05-21
Teenage golfer Ji wins first pro title in Tianjin
China's 19-year-old golfer Ji Yuai captured her first pro title on Saturday, carding a final-rou2024-05-21Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
CAIRO (AP) — Human rights experts working for the United Nations on Monday urged Yemen’s Houthi rebe2024-05-21Spicer, Owusu help Toronto rally to beat Orlando City 2
ORLANDO, Fla. (AP) — Tyrese Spicer and Prince Owusu scored in the closing minutes to help Toronto FC2024-05-21
atest comment